Electrocore LLC (ECOR)vsEdwards Lifesciences Corp (EW)
ECOR
Electrocore LLC
$8.72
-12.27%
HEALTHCARE · Cap: $72.34M
EW
Edwards Lifesciences Corp
$85.96
-1.70%
HEALTHCARE · Cap: $49.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 17963% more annual revenue ($6.30B vs $34.90M). EW leads profitability with a 17.4% profit margin vs -44.1%. EW earns a higher WallStSmart Score of 61/100 (C+).
ECOR
Avoid26
out of 100
Grade: F
EW
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+84.1%
Fair Value
$34.25
Current Price
$8.72
$25.53 discount
Margin of Safety
+68.7%
Fair Value
$253.29
Current Price
$85.96
$167.33 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 42.6% year-over-year
Conservative balance sheet, low leverage
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -478.7% — below average capital efficiency
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ECOR
The strongest argument for ECOR centers on Revenue Growth, Debt/Equity. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : ECOR
The primary concerns for ECOR are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Key Dynamics to Monitor
ECOR profiles as a hypergrowth stock while EW is a growth play — different risk/reward profiles.
ECOR carries more volatility with a beta of 0.87 — expect wider price swings.
ECOR is growing revenue faster at 42.6% — sustainability is the question.
ECOR generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 26/100), backed by strong 17.4% margins and 16.7% revenue growth. ECOR offers better value entry with a 84.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Electrocore LLC
HEALTHCARE · MEDICAL DEVICES · USA
electroCore, Inc., a commercial-stage medical device company, is dedicated to the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is headquartered in Rockaway, New Jersey.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?